1. In Vivo
  2. >>Global Vision

Versicor/Biosearch Italia: Merging as Equals

 
• By Melanie Senior

Versicor had wanted to buy its partner Biosearch Italia for more than a year prior to July's deal. But it had to wait for its market capitalization to fall closer in line with that of the Italian biotech so that the transaction could qualify as a "merger of equals."

Vicuron Pharmaceuticals Inc.'s estimated €230 million ($234 million) all-stock acquisition in July of anti-infectives counterpart Biosearch Italia SPA is easily justified [See Deal]. The companies had been collaborating since February 1998, when they formed a joint venture called Biocor to identify anti-infective leads from Biosearch Italia's natural products library and apply Versicor's downstream combinatorial chemistry to optimize them [See Deal]. At the same time, Versicor in-licensed co-development rights and US marketing rights to Biosearch Italia's antibiotic dalbavancin, now in phase II for methicillin resistant Staphylococcus aureus (MRSA) infections in skin, soft tissue and the bloodstream [See Deal]. The drug's formulation as a once-a-week injectable and its high potency could also offer significant advantages over vancomycin in treating MRSA.

Buying Biosearch Italia outright saves Versicor paying the group royalties on dalbavancin, which it expects to file at the end...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.